Skip to content
Recall Observatory FDA recall evidence

Drug product

Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.

D-1533-2020

August 14, 2020

Class II

Product summary

Firm
Hikma Pharmaceuticals USA Inc.
Event
Event 86243
Status
Terminated
Classification
Class II
Quantity
97,890 vials
Official record key
drug-enforcement:D-1533-2020

Official wording

Reason: Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.

Code information: Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021

Distribution pattern: Nationwide in the U.S.

Derived failure modes

  • Potency or specification failure

    reason.potency_specification_failure · v1.0.0

    Out-of-Specification